BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Rhea-AI Summary
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, announced a poster presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting in Washington, DC, from December 13–15, 2024.
The presentation, titled Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC, will be delivered by a team of authors including Julia Rotow, Grace K. Dy, and others.
Details of the presentation include:
- Poster Number: PP01.03
- Session Type: Poster Reception
- Session Date and Time: Saturday, December 14, 2024, from 5:40 P.M. – 6:40 P.M. ET
Materials from the presentation will be available on the “Publication” section of BioAtla’s website after the event.
Positive
- BioAtla's participation in the IASLC 2024 meeting highlights the company's ongoing research and development efforts.
- The presentation on Mecbotamab Vedotin may provide valuable insights into the treatment of advanced NSCLC, potentially boosting investor confidence.
Negative
- None.
News Market Reaction – BCAB
On the day this news was published, BCAB declined 0.62%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024.
Presentation Details:
| Title: | Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC | |
| Authors: | Julia Rotow, Grace K. Dy, Edwin Yau, Elaine Shum, Mariam Alexander, Karen L. Reckamp, Roland Leung, Dariusz M. Kowalski, Jose Fuentes Pradera, Jon Zugazagoitia Fraile, Kyechin Chen, Kartik Aysola, D. Ross Camidge | |
| Poster Number: | PP01.03 | |
| Session Type: | Poster Reception | |
| Session Date and Time: | Saturday, December 14, 2024 from 5:40 P.M. – 6:40 P.M. ET |
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What event will BioAtla present at?
When and where is the IASLC 2024 meeting?
What is the focus of BioAtla's presentation at the IASLC 2024 meeting?
When will BioAtla's poster presentation take place?
Where can the presentation materials be accessed?
